Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GENZYME - THE KING OF THE BIOTECHS -- Ignore unavailable to you. Want to Upgrade?

To: Racso who wrote (366)	4/28/1999 4:54:00 PM
From: VincentTH	Read Replies (1) \| Respond to of 410

Racso, Agreed 100% on your fundamental analysis. However, the stock has a disturbing pattern of pushing higher in the morning only to fade at the close, looking like somebody is trying to get out of a large position. (I don't think it's the CEO, because with GENZ volume, selling a position of 300K is not that hard. On the other hand, I have not found the F4 though, so I am not sure the CEO's selling is done.) I am currently trading this stock, buying sub 38 and selling above 39. Good luck in your investment, //V

To: Racso who wrote (366)	4/29/1999 9:37:00 AM
From: Harold Engstrom	Read Replies (1) \| Respond to of 410

Rasco, FWIW, the comparative numbers you cite don't tell the whole story. For example, although Genzyme's price/book is lower than the other companies you cite, their book value is comprised of a much higher ratio of property, plant and equipment than the others. A price/cash ratio would yield a flatter comparison. PE can be explained by Genzyme's low growth rate relative to most of the others. And the price/sales ratio can also be explained by Genzyme's selling of medical products as well as biopharmaceuticals - the ratio should be lower for this reason. I don't think the numbers speak for themselves, but that doesn't mean Genzyme isn't a good investment. Good luck, Harold